Janssen Announces Respiratory Syncytial Virus (RSV) Adult Vaccine Candidate Maintains High Efficacy Regardless of Lower Respiratory Tract Disease Severity

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced additional vaccine efficacy and safety data from its Phase 2b CYPRESS...

Related Keywords

United States ,America ,Annr Falsey ,Jennifer Mcintyre ,Katie Buckley ,Asia Pacific ,None Of The Janssen Pharmaceutical Companies ,Drug Administration ,University Of Rochester School Medicine ,Janssen Research Development ,Janssen Pharmaceutical Companies ,Janssen Pharmaceutical Companies Of Johnson ,Exchange Commission ,Companies Of Johnson ,European Scientific Working Group On Influenza ,Johnson ,Eighth European Scientific Working Group ,Penny Heaton ,Global Therapeutic Area Head ,Janssen Research ,Rochester School ,North America ,Breakthrough Therapy Designation ,European Medicines Agency ,Medicinal Products ,Human Use ,Respiratory Syncytial Virus ,Latin America ,Pharmaceutical Companies ,Infectious Diseases ,Private Securities Litigation Reform Act ,Annual Report ,Note Regarding Forward Looking ,Quarterly Report ,Respiratory Syncytial Virus Infection ,Healthy Adults ,Single Immunization ,Human Challenge ,Janssen Pharmaceutical Companies Of Johnson Amp ,